Why Choose Credelio?
- Credelio is gentle enough for dogs and puppies as small as 4.4 lbs or greater and as young as 8 weeks of age.
- Our active ingredient extra-purification process means your dog gets only what it needs in the final product formulation.
- Powerful protection starts to kill ticks (l. ricinus) and fleas in just 4 hours.
- With a tasty chewable, keeping your dog protected is easy for you both.
Credelio Dosing Table
Credelio is available in 5 different weight classes, enabling you to offer pet owners convenient and easy administration for dogs 4.4 lbs and up.
|Dog weight - Lotilaner / tablet|
|4.4-6.0 lbs - 56.25 mg|
|6.1-12.0 lbs - 112.5 mg|
|12.1-25.0 lbs - 225 mg|
|25.1-50.0 lbs - 450 mg|
|50.1-100.0 lbs - 900 mg|
|Greater than 100.0 lbs - -|
|Dog weight - Tablet administered|
|4.4-6.0 lbs - one|
|6.1-12.0 lbs - one|
|12.1-25.0 lbs - one|
|25.1-50.0 lbs - one|
|50.1-100.0 lbs - one|
|Greater than 100.0 lbs - Administer the appropriate combination|
|Dog weight||4.4-6.0 lbs||6.1-12.0 lbs||12.1-25.0 lbs||25.1-50.0 lbs||50.1-100.0 lbs||Greater than 100.0 lbs|
|Lotilaner / tablet||56.25 mg||112.5 mg||225 mg||450 mg||900 mg||-|
|Tablet administered||one||one||one||one||one||Administer the appropriate combination|
For full efficacy against ticks and fleas, instruct pet owners to always give their dog Credelio with food or within 30 minutes of a meal. The presence of food ensures that peak blood levels and exposures are achieved, which is necessary for initial and ongoing efficacy.
Credelio should be administered once a month, every month, to dogs and puppies 8 weeks of age and older and 4.4 pounds or greater to provide year-round protection.
Credelio’s active ingredient, lotilaner, is a member of the isoxazoline family, a novel class of parasiticides that targets nerve receptors of ticks and fleas for powerful protection.²
Credelio® (lotilaner) for Dogs
Indications for Credelio® (lotilaner)
Credelio® (lotilaner) kills adult fleas and is indicated for the treatment and prevention of flea infestations (Ctenocephalides felis) and the treatment and control of tick infestations [Amblyomma americanum (lone star tick), Dermacentor variabilis (American dog tick), Ixodes scapularis (black-legged tick) and Rhipicephalus sanguineus (brown dog tick)] for one month in dogs and puppies 8 weeks of age and older and weighing 4.4 pounds or greater.
Important Safety Information (ISI)
Lotilaner is a member of the isoxazoline class. This class has been associated with neurologic adverse reactions including tremors, ataxia, and seizures. Seizures have been reported in dogs receiving this class of drugs, even in dogs without a history of seizures. Use with caution in dogs with a history of seizures or neurologic disorders. The safe use of Credelio® in breeding, pregnant or lactating dogs has not been evaluated. The most frequently reported adverse reactions are weight loss, elevated blood urea nitrogen, polyuria, and diarrhea. For full prescribing information see the Credelio® package insert.
Indications for Interceptor® Plus (milbemycin oxime/praziquantel)
Interceptor Plus® Plus (milbemycin oxime/praziquantel) is indicated for the prevention of heartworm disease caused by Dirofilaria immitis and for the treatment and control of adult roundworm (Toxocara canis, Toxascaris leonina), adult hookworm (Ancylostoma caninum), adult whipworm (Trichuris vulpis), and adult tapeworm (Taenia pisiformis, Echinococcus multilocularis, Echinococcus granulosus and Dipylidium caninum) infections in dogs and puppies 6 weeks or older and 2 lbs or greater.
Important Safety Information
Treatment with fewer than 6 monthly doses after the last exposure to mosquitoes may not provide complete heartworm prevention. Prior to the administration of Interceptor Plus, dogs should be tested for existing heartworm infections. The safety of Interceptor® Plus has not been evaluated in dogs used for breeding or in lactating females. The following adverse reactions have been reported in dogs after administration of milbemycin oxime or praziquantel: vomiting, diarrhea, depression/lethargy, ataxia, anorexia, convulsions, weakness, and salivation. For full prescribing information see the Interceptor® Plus package insert.